PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.62%
Revenue growth above 1.5x MRVL's 2.48%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
14.26%
Gross profit growth above 1.5x MRVL's 0.99%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
51.57%
Positive EBIT growth while MRVL is negative. John Neff might see a substantial edge in operational management.
129.37%
Positive operating income growth while MRVL is negative. John Neff might view this as a competitive edge in operations.
82.32%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
84.37%
EPS growth above 1.5x MRVL's 6.25%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
81.25%
Diluted EPS growth of 81.25% while MRVL is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
-0.36%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.53%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
33.67%
Dividend growth of 33.67% while MRVL is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
87.22%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
109.06%
Positive FCF growth while MRVL is negative. John Neff would see a strong competitive edge in net cash generation.
104.15%
10Y revenue/share CAGR under 50% of MRVL's 476.56%. Michael Burry would suspect a lasting competitive disadvantage.
8.82%
5Y revenue/share CAGR under 50% of MRVL's 29.83%. Michael Burry would suspect a significant competitive gap or product weakness.
-4.55%
Negative 3Y CAGR while MRVL stands at 40.65%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
179.43%
10Y OCF/share CAGR under 50% of MRVL's 7584.17%. Michael Burry would worry about a persistent underperformance in cash creation.
55.41%
Below 50% of MRVL's 404.29%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
31.35%
3Y OCF/share CAGR above 1.5x MRVL's 14.56%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
754.81%
Net income/share CAGR at 75-90% of MRVL's 943.93%. Bill Ackman would press for strategic moves to boost long-term earnings.
34.33%
Below 50% of MRVL's 272.24%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-6.00%
Negative 3Y CAGR while MRVL is 75.68%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
58.52%
10Y equity/share CAGR at 50-75% of MRVL's 106.09%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
32.67%
5Y equity/share CAGR at 50-75% of MRVL's 55.48%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
24.26%
3Y equity/share CAGR at 50-75% of MRVL's 37.49%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
1208.79%
Dividend/share CAGR of 1208.79% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
180.15%
Dividend/share CAGR of 180.15% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
130.21%
3Y dividend/share CAGR of 130.21% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
11.85%
Our AR growth while MRVL is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
1.18%
We show growth while MRVL is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-1.54%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
1.43%
BV/share growth above 1.5x MRVL's 0.64%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-9.11%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.16%
Our R&D shrinks while MRVL invests at 3.21%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
2.61%
SG&A growth well above MRVL's 1.49%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.